Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET

Company Participants

Warren Huff - Chief Executive Officer

Colin Meyer - Chief Innovation Officer

Dawn Bir - Chief Commercial Officer

Manmeet Soni - President

Conference Call Participants

Yigal Nochomovitz - Citigroup

Madhu Kumar - Goldman Sachs

Charles Duncan - Cantor Fitzgerald

Annabel Samimy - Stifel

Maury Raycroft - Jefferies

Operator

Thank you for standing by and welcome to Reata Pharmaceuticals Second Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investors section of Reata's website at reatapharma.com.

Before the company proceeds with its remarks, please note that forward-looking statements disclosure in the company's press release. There are many factors that could cause results to differ from expectations, including those noted in the company’s SEC filings. On today's conference call non-GAAP financial measures will be used to help investors understand the business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in the Reata's earnings release and presentation from today, which again can be found in Reata's website.

Today's statements are not guarantees of future outcomes. Please also note that any comments made on today's call apply only as of today, August 8, 2022, and may no longer be accurate at the time of any webcast replay or transcript re-reading. Following the prepared remarks, we will open the call up for questions. We ask that you please limit yourself to one question and one follow-up so that we can accommodate as many questions as possible.

We are joined today by Warren Huff, Reata’s Chief Executive Officer; Manmeet Soni, President; Colin Meyer, Chief Innovation Officer; and Seemi Khan, Chief Medical officer; and Dawn Bir; Chief Commercial Officer.

At this time, I would like to turn the call over to Warren Huff.

Warren Huff

Good morning everyone. We thank you for joining us today for our quarterly update. I'll start on Slide 4. As you know, we're developing omaveloxolone, or Omav, a small molecule Nrf2 activator for the treatment of patients with Friedreich's ataxia, or FA. FA is a relentlessly progressive and debilitating neuromuscular disorder, which affects approximately 5,000 patients in the United States. There are no approved therapies and patients typically become dependent on walkers and then wheelchairs in their mid-20s and unfortunately pass-away from the disease in their mid-30s.